Clinical Trials Logo
  1. Home
  2. Lung Cancer, Non-Small Cell
  3. NCT00678977

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

Lung Cancer, Non-Small Cell Clinical Trial

Official title:
A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

Clinical Trial Summary

This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the optimal tolerated regimen(OTR) of pazopanib in combination with gemcitabine (Arm A) or pazopanib, gemcitabine, and cisplatin (Arm B) in patients with advanced solid tumors. Patients will be enrolled in cohorts of 3 to receive escalating doses of pazopanib and gemcitabine or pazopanib, gemcitabine and cisplatin. Dose escalation schemas for each study arm are described in the protocol. For each arm, the OTR will be defined as the highest dose combination of the agents where no more than one out of six patients experiences a dose-limiting toxicity. Six to twelve additional patients in each arm will be studied with the OTR to evaluate toxicity and pharmacokinetics. This will allow an assessment of potential drug-drug interactions. Antitumor activity will be assessed using RECIST criteria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00678977
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date April 3, 2008
Completion date June 30, 2011
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05598528 - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Completed NCT03836469 - Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
Completed NCT01772225 - NSCLC Burden of Illness Study N/A
Completed NCT01362296 - An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Recruiting NCT03803137 - Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection N/A
Completed NCT00528281 - A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase Phase 1
Not yet recruiting NCT04592666 - Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer Phase 2
Terminated NCT00480025 - GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer Phase 3
Active, not recruiting NCT05784142 - Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC) Phase 2
Active, not recruiting NCT04475939 - Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer Phase 3
Withdrawn NCT01938456 - Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer Phase 1
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Recruiting NCT05565378 - A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer Phase 2
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Completed NCT00367679 - Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer Phase 2
Terminated NCT00073008 - A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT04581824 - Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT00619424 - A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04940936 - Shared Decision Making on Radiation Dose for Lung Malignancies N/A